[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023
Basel, 3 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Matt Sause (45), currently Head of Roche Diagnostics ’ North America Region, will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.Thomas Schinecker, the incumbent CEO of the Diagnostics Division and new Roche CEO as of 15 March 2023: “Matt Sause’s career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America in both the Diagnostics and Pharma divisions. His combination of scientific knowledge with commercial experience makes him a...
Source: Roche Investor Update - October 3, 2022 Category: Pharmaceuticals Source Type: news
Regeneration after rare head and neck cancer
Alison O'Neill's love for life is as infectious as her grateful attitude. "I've been blessed beyond measure. I absolutely love and appreciate life to the fullest." says Alison. With a bright outlook and a healthy lifestyle, Alison never expected that a small blemish on her right cheek would trigger a big change in her life — a twist of fate that would lead her on the path to regenerative biotherapeutics. Watch: Regeneration after rare head… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 16, 2022 Category: Databases & Libraries Source Type: news
Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer
(MedPage Today) -- PARIS -- Combining a PD-1 inhibitor with standard chemoradiotherapy (CRT) failed to significantly improve survival outcomes in unresectable locally advanced head and neck squamous cell carcinoma, results of the phase III KEYNOTE... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2022 Category: Hematology Source Type: news
Do PET/CT reports contain riddles for oncologists?
Key information on PET/CT imaging reports on whether head and neck cancer patient...Read more on AuntMinnie.comRelated Reading:
Dual-tracer PET/CT shows promise in cancer imaging
CT finds secondary lung disease in head and neck cancer survivors
Second-look PET/CT catches cancer spread
PET/CT shows promise predicting outcomes in head, neck cancer
PSMA-PET reveals new salivary glands (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 23, 2022 Category: Radiology Source Type: news
Patient with cancer receives first 3D-printed titanium jaw
A patient with head and neck cancer received the first 3D-printed titanium lowe...Read more on AuntMinnie.com (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 10, 2022 Category: Radiology Source Type: news
Taste Dysfunction in Head and Neck Cancer Due to Radiation Dose Taste Dysfunction in Head and Neck Cancer Due to Radiation Dose
Lowering the dose of radiotherapy delivered to the oral cavity could reduce the risk of taste dysfunction in patients with head and neck cancer, say researchers.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 5, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Expert Alert: Options for laryngeal regeneration
PHOENIX, Ariz. — Mayo Clinic is using 3D printing as a new option to heal the larynx after cancer or traumatic injury. David Lott, M.D., a Mayo Clinic otolaryngologist and head and neck surgeon, is an expert who can speak about a pioneering procedure using 3D bioimplants and tissue engineering to regenerate the larynx, more commonly known as the voice box. Dr. Lott also is the associate director of the Center for Regenerative Medicine at… (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - August 2, 2022 Category: Hospital Management Source Type: news
The Latest Breakthroughs That Could Help Bladder Cancer Patients
Toward the end of the 19th century, a New York City surgeon named Dr. William Coley purposely injected one of his patients with streptococcal bacteria. Coley wasn’t crazy. He hoped the bacterial infection would stimulate an immune response that would slow the spread of his patient’s cancer, which was inoperable. The experiment worked; the patient’s tumor shrank.
For the next 40 years, Coley and his research collaborators would test similar remedies on more than 1,000 cancer patients. They had failures but also many successes, especially among people with bone or soft-tissue cancers. Today, Coley is someti...
Source: TIME: Health - July 27, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Scientists create nanoparticle that helps fight solid tumors
Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle. Solid tumors are found in cancers such as breast, head and neck, and colon cancer.
In the study, Xin Ming, associate professor of cancer biology at Wake Forest University School of Medicine, and his team used a nanoparticle to deliver a small molecule called ARL67156 to promote an anti-tumor immune response in mouse models of colon,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 14, 2022 Category: Pharmaceuticals Authors: Atrium Health Wake Forest Baptist Source Type: news
Mitochondrial Protein Fuels Spread of Head and Neck Cancer
Head and neck cancer cells lacking the peptide involved in energy production were less likely to metastasize in mice. (Source: The Scientist)
Source: The Scientist - July 8, 2022 Category: Science Tags: News & Opinion Source Type: news
Mitochondrial Protein Fuels Spread of Head and Neck Cancer & nbsp;
Removing a protein involved in energy production from the mitochondria of head and neck cancer cells drastically reduced the number of cells that metastasized in mice. (Source: The Scientist)
Source: The Scientist - July 8, 2022 Category: Science Tags: News & Opinion Source Type: news
What does the new cancer vaccine trial mean for a cure to the illness?
None of the eight head and neck cancer sufferers, who had a high chance of relapse, have seen their tumours return four months after getting the vaccine in a trial at a UK cancer centre. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2022 Category: Consumer Health News Source Type: news
European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news
Cost of living crisis will lead to more cancer patient survival rates
THE spiralling cost-of-living crisis will lead to more cancer patients relapsing and could hit survival rates, research suggests. A study of 555 Canadian patients with head and neck cancer found a low income was detrimental to their chances of recovery. (Source: Daily Express - Health)
Source: Daily Express - Health - June 7, 2022 Category: Consumer Health News Source Type: news
